ABBV [NYSE]
AbbVie Inc.
IndexS&P 500 P/E22.30 EPS (ttm)6.97 Insider Own0.10% Shs Outstand1.77B Perf Week2.99%
Market Cap276.15B Forward P/E12.94 EPS next Y12.01 Insider Trans-33.13% Shs Float1.76B Perf Month-4.21%
Income12.40B PEG10.45 EPS next Q3.43 Inst Own70.20% Short Float0.75% Perf Quarter8.72%
Sales56.73B P/S4.87 EPS this Y137.00% Inst Trans1.75% Short Ratio1.71 Perf Half Y32.91%
Book/sh9.19 P/B16.92 EPS next Y-14.35% ROA8.50% Target Price164.73 Perf Year33.01%
Cash/sh4.26 P/C36.47 EPS next 5Y2.13% ROE85.80% 52W Range105.56 - 175.91 Perf YTD14.82%
Dividend5.64 P/FCF21.95 EPS past 5Y12.20% ROI17.90% 52W High-11.62% Beta0.78
Dividend %3.63% Quick Ratio0.70 Sales past 5Y17.00% Gross Margin69.80% 52W Low47.28% ATR4.82
Employees50000 Current Ratio0.80 Sales Q/Q4.10% Oper. Margin32.70% RSI (14)51.12 Volatility2.40% 2.93%
OptionableYes Debt/Eq4.51 EPS Q/Q26.20% Profit Margin21.90% Rel Volume0.84 Prev Close153.50
ShortableYes LT Debt/Eq3.90 EarningsApr 29 BMO Payout75.90% Avg Volume7.69M Price155.47
Recom2.10 SMA201.08% SMA50-1.17% SMA20018.32% Volume6,565,644 Change1.28%
May-06-22Downgrade Daiwa Securities Outperform → Neutral $150
Apr-06-22Resumed Morgan Stanley Overweight $192
Feb-28-22Downgrade UBS Buy → Neutral $129 → $147
Feb-03-22Reiterated Goldman Neutral $117 → $122
Feb-03-22Reiterated BofA Securities Neutral $135 → $138
Feb-03-22Reiterated BMO Capital Markets Outperform $153 → $154
Feb-03-22Reiterated Barclays Equal Weight $133 → $150
Jan-13-22Initiated Redburn Buy
Jan-12-22Reiterated BMO Capital Markets Outperform $134 → $153
Dec-09-21Resumed Wells Fargo Overweight $165
Nov-23-21Upgrade Societe Generale Hold → Buy $172
Jul-27-21Resumed Truist Buy $118
Apr-07-21Resumed RBC Capital Mkts Outperform $135
Nov-10-20Resumed Bernstein Outperform $120
Sep-29-20Initiated Berenberg Hold $98
Jun-23-20Upgrade Atlantic Equities Neutral → Overweight $115
Jun-09-20Upgrade Wolfe Research Peer Perform → Outperform
Jun-02-20Upgrade Argus Hold → Buy $115
May-18-20Resumed BofA/Merrill Neutral $95
May-12-20Upgrade JP Morgan Neutral → Overweight $105
May-16-22 05:53PM  
04:26PM  
12:27PM  
09:13AM  
08:00AM  
07:30AM  
May-14-22 10:30AM  
May-13-22 04:05PM  
08:10AM  
05:52AM  
May-12-22 02:47PM  
11:39AM  
08:30AM  
08:02AM  
May-11-22 06:26PM  
01:05PM  
08:51AM  
08:45AM  
07:52AM  
May-10-22 07:30PM  
05:03PM  
02:58PM  
10:45AM  
May-09-22 01:49PM  
08:15AM  
May-06-22 10:24AM  
09:02AM  
07:33AM  
May-05-22 09:00AM  
08:15AM  
05:52AM  
May-04-22 05:52AM  
May-03-22 09:06AM  
May-02-22 04:09PM  
Apr-30-22 11:00AM  
05:57AM  
05:00AM  
Apr-29-22 04:46PM  
04:04PM  
03:54PM  
02:44PM  
01:46PM  
11:59AM  
11:20AM  
10:43AM  
10:02AM  
09:40AM  
09:05AM  
08:07AM  
07:48AM  
07:45AM  
07:43AM  
06:10AM  
Apr-28-22 06:11PM  
10:53AM  
09:35AM  
08:30AM  
08:00AM  
07:35AM  
Apr-27-22 08:35AM  
07:00AM  
Apr-26-22 01:11PM  
11:15AM  
09:46AM  
09:31AM  
07:36AM  
06:30AM  
06:16AM  
Apr-25-22 05:45PM  
02:37PM  
09:29AM  
09:17AM  
Apr-22-22 03:00PM  
06:20AM  
Apr-21-22 05:17PM  
11:38AM  
Apr-20-22 11:31AM  
09:17AM  
08:00AM  
07:00AM  
06:40AM  
Apr-19-22 05:45PM  
10:05AM  
09:23AM  
08:30AM  
Apr-18-22 09:06AM  
07:20AM  
Apr-15-22 11:45AM  
Apr-14-22 04:15PM  
10:01AM  
09:23AM  
08:00AM  
07:00AM  
06:09AM  
05:55AM  
Apr-13-22 06:53PM  
05:26PM  
04:21PM  
04:15PM  
12:13PM  
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behcet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
SEVERINO MICHAELVice ChairmanMay 10Option Exercise59.60100,0005,960,468252,103May 10 05:05 PM
SEVERINO MICHAELVice ChairmanMay 10Sale152.28100,00015,227,966152,103May 10 05:05 PM
SEVERINO MICHAELVice ChairmanMay 09Option Exercise56.21100,0005,621,478252,103May 10 05:05 PM
SEVERINO MICHAELVice ChairmanMay 09Sale150.28100,00015,027,710152,103May 10 05:05 PM
SEVERINO MICHAELVice ChairmanMay 06Option Exercise54.55100,0005,454,790252,103May 10 05:05 PM
SEVERINO MICHAELVice ChairmanMay 06Sale150.81100,00015,080,612152,103May 10 05:05 PM
Stewart Jeffrey RyanEVP, Chief Commercial OfficerMar 24Option Exercise58.8827,6901,630,38788,631Mar 25 05:09 PM
Stewart Jeffrey RyanEVP, Chief Commercial OfficerMar 24Sale159.2027,6904,408,37560,941Mar 25 05:09 PM
Durkin Brian LVP, ControllerMar 09Option Exercise79.0211,682923,11237,722Mar 11 05:05 PM
Durkin Brian LVP, ControllerMar 09Sale150.0118,6282,794,30119,094Mar 11 05:05 PM
Gosebruch Henry OEVP, Chief Strategy OfficerMar 01Sale148.2615,0002,223,83641,623Mar 01 06:14 PM
Michael Robert A.Vice ChairmanMar 01Sale148.2543,1056,390,24737,877Mar 01 06:07 PM
Gosebruch Henry OEVP, Chief Strategy OfficerMar 01Sale147.2925,0003,682,18916,623Mar 02 05:03 PM
Stewart Jeffrey RyanEVP, Chief Commercial OfficerMar 01Sale148.2521,4883,185,59960,941Mar 01 06:08 PM
Strom Carrie CSVP & Pres Global Allerg AesthFeb 07Sale141.172,396338,24342,499Feb 08 05:13 PM
Durkin Brian LVP, ControllerDec 20Option Exercise61.367,180440,56528,295Dec 21 05:29 PM
Durkin Brian LVP, ControllerDec 20Sale128.5111,7901,515,13316,505Dec 21 05:29 PM
Schumacher Laura JVice ChairmanDec 17Option Exercise57.14181,67010,381,361394,673Dec 21 05:21 PM
Schumacher Laura JVice ChairmanDec 17Sale130.24181,67023,660,678213,003Dec 21 05:21 PM
Stewart Jeffrey RyanEVP, Chief Commercial OfficerDec 15Sale128.002,152275,45647,104Dec 17 05:01 PM
Sorg Elaine K.SVP, US Commercial OperationsDec 13Sale125.856,458812,7390Dec 14 05:01 PM
GONZALEZ RICHARD AChairman of the Board and CEODec 09Option Exercise61.36174,10010,682,776550,697Dec 10 05:02 PM
GONZALEZ RICHARD AChairman of the Board and CEODec 09Sale123.23174,10021,453,641376,597Dec 10 05:02 PM
RICHMOND TIMOTHY J.EVP, Chief HR OfficerDec 06Option Exercise58.8850,3502,964,60850,350Dec 08 05:01 PM
RICHMOND TIMOTHY J.EVP, Chief HR OfficerDec 06Sale120.0050,3506,042,0000Dec 08 05:01 PM
AUSTIN ROXANNE SDirectorNov 03Sale117.2320,0002,344,60049,284Nov 04 05:35 PM
AUSTIN ROXANNE SDirectorNov 02Sale116.3851,8446,033,38469,284Nov 04 05:35 PM
Sorg Elaine K.SVP, US Commercial OperationsAug 23Option Exercise114.367,080809,66918,675Aug 25 06:08 PM
Sorg Elaine K.SVP, US Commercial OperationsAug 23Sale120.0013,0801,569,60011,595Aug 25 06:08 PM
Strom Carrie CSVP & Pres Global Allerg AesthAug 23Sale120.005,057606,84051,047Aug 25 06:08 PM
SALEKI-GERHARDT AZITAEVP, OperationsMay 24Option Exercise34.9386,9203,036,230203,204May 26 05:20 PM
SALEKI-GERHARDT AZITAEVP, OperationsMay 24Sale116.2986,92010,108,033116,284May 26 05:20 PM